SCHEMBL16091818

SCHEMBL16091818

CC(C)[C@H](NC(=O)CCCCCCON)C(=O)NC(CCCNC(N)=O)C(=O)Nc1ccc(COC(N)=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 8/20 0.41
▸ SIRT1 Q96EB6 7/20 0.41
▸ SIRT3 Q9NTG7 3/20 0.41
▸ NPY5R Q15761 4/20 0.41
▸ NPY1R P25929 3/20 0.41
▸ NPY4R P50391 3/20 0.41
▸ NPY2R P49146 1/20 0.41
▸ SIRT5 Q9NXA8 1/20 0.40
▸ FAP Q12884 1/20 0.40
▸ MAP1LC3B Q9GZQ8 1/20 0.40
▸ FURIN P09958 2/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16156452 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL18556695 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL26348585 0.91 SIRT5 (0.41) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL19647265 0.90 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL22479752 0.90 SIRT1 (0.47) SIRT2SIRT1SIRT3SIRT5FURIN
SCHEMBL14887361 0.88 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL19687799 0.88 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL19687798 0.88 SIRT2 (0.42) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL23843840 0.88 FAP (0.48) SIRT2SIRT1SIRT3NPY5RNPY1R
SCHEMBL14978945 0.88 FAP (0.48) SIRT2SIRT1SIRT3NPY5RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790268-B2 Fc containing polypeptides with altered glycosylation and reduced effector function GENZYME CORPORATION (US) 2017-10-17 — — US disclosed
US-20170107276-A9 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION GENZYME CORPORATION (US) 2017-04-20 — — US disclosed
US-20140271676-A1 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION GENZYME CORPORATION (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140271676-A1 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION FCGR3B, FCGRT, FCGR2A SIRT2 4647/4885SIRT1 4563/4885SIRT3 4649/4885
US-20170107276-A9 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION FCGR3B, FCGRT, FCGR2A SIRT2 4647/4885SIRT1 4563/4885SIRT3 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback